Little is known on the phylogenetic relationship between diagnostic and relapse clones of diffuse large Bcell lymphoma (DLBCL). We applied high throughput sequencing (HTS) of the VDJ locus of Immunoglobulin heavy chain (IGHV) on 14 DLBCL patients with serial samples, including tumor biopsies and/or peripheral blood mononuclear cells (PBMC). Phylogenetic data were consolidated with targeted sequencing and cytogenetics. Phylogeny clearly showed that DLBCL relapse could occur according either an early or a late divergent mode. These two modes of divergence were independent from the elapsed time between diagnosis and relapse. We found no significant features for antigen selection pressure in complementary determining region both at diagnosis and relapse for 9/12 pairs and a conserved negative selection pressure for the three remaining cases. Targeted HTS and conventional cytogenetics revealed a branched vs. linear evolution for 5/5 IGHV early divergent cases, but unexpected such "oncogenetic" branched evolution could be found in at least 2/7 IGHV late divergent cases. Thus, if BCR signaling is mandatory for DLBCL emergence, oncogenetic events under chemotherapy selection pressure may be the main driving forces at relapse. Finally, circulating subclones with divergent IGHV somatic hypermutations patterns from initial biopsy could be detected in PBMC at diagnosis for 4/6 patients and, for two of them, at least one was similar to the ones found at relapse. This study highlights that oncogenetic intraclonal diversity of DLBCL should be evaluated beyond the scope a single biopsy and represents a rationale for future investigations using peripheral blood for lymphoid malignancies genotyping.
(Variable) gene, one IGHD (Diversity) gene and one IGHJ (Joining) gene for the IgH chain, and only one IGLV and one IGLJ gene for IgL [10] . V(D)J rearrangement occurs in the B-cell progenitor of the bone marrow, independently from the antigen (Ag) and is characterized by imprecise DNA joining. Thus, the process produces unique clonotypes. During immune response, reactive B-cells are recruited into the germinal center (GC) where their V(D)J rearrangement is submitted to somatic hypermutations (SHM), mediated by activation-induced cytidine deaminase (AICDA), that improve BCR affinity for its Ag [11] .
Based on this physiological maturation of V(D)J rearrangement, previous studies had demonstrated several years ago that two divergence modes could be observed during the long course of follicular lymphomas (FLs). Indeed, FLs could relapse either according a direct and rapid evolution from the dominant clone or following an indirect evolution arising from earlier subclones, usually after years of remission [12, 13] . Very recently, a similar scenario has been demonstrated in DLBLCs [14] . Using Ig high throughput sequencing (Ig-HTS), the authors clearly showed that DLBCL relapse could also arise either from a distantly-related clone independently evolved from a common precursor (early divergence), or from a clone more closely related to that of initial diagnosis (late divergence).
In order to gain new insights into the evolution of intraclonal diversity of DLBCL, we retrospectively compared tumoral architecture of paired diagnosis and relapse samples. Ig-HTS combined with phylogenetic trees confirmed the two modes of divergence in DLBCL. Here, we consolidated these data by both targeted sequencing and conventional cytogenetics. Analysis of somatic hypermutations patterns revealed the absence of Ag selection pressure in these sequences. Finally, Ig-HTS applied to paired PBMC samples highlighted that divergent and relapse-related clone could be frequently detected in peripheral blood at diagnosis, thus raising the question of the scale to consider to explore DLBCL genotype, notably in a purpose of targeted therapy.
Methods
Patients. Fourteen patients diagnosed from 1994 to 2014 in our institution were retrospectively included, each identified with a unique patient number (UPN). Main characteristics are presented in Supporting Information Table I . This study received the approval of our institutional review board (#1502B).
Nucleic acids and cytogenetics. DNA was extracted using proteinase K, followed by salt and ethanol precipitation and stored at 2208C in 10 mM Tris-Cl 1 mM EDTA (pH 8) buffer. RNA was isolated using the RNA NOW kit (Biogentex, Seabrook, TX) and stored at 2808C in water. Synthesis of cDNA was performed using Moloney murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA). Rbanded metaphases were karyotyped and chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature [15] (Supporting Information Table II) .
Cell of origin (COO) molecular classification. The COO classification (GCB vs. ABC) was established with a custom VeraCode DASL gene expression assay (Illumina, San Diego, CA), and a Linear Prediction Score (LPS) model as previously developed [16] . Briefly, our custom assay evaluated the levels of expression of a total of 96 genes. Among them, 19 genes previously reported as differentially expressed between GCB and ABC subtypes [17, 18] were used to discriminate the COO of tumor B-cells. Details and complete list of genes used in this custom dataset are available in the Supporting Information Methods. In complement to the molecular COO classification, immunohistochemistry (IHC) using the Hans algorithm was also performed [19] . Results of both molecular and IHC classifications are presented in Supporting Information Table III ). Of note, as this method for COO classification is based on hierarchical clustering, it is very dissimilar from the Bayesian classifier used by the majority of investigators and thus the subtyping result may be different.
VDJ high throughput sequencing (i.e., Ig-HTS). VDJ rearrangement amplification was performed from 50 ng of genomic DNA using V-gene family-specific VHFR1 and JH consensus BIOMED-2 primers. Deep sequencing of 400 bases length amplicons was performed on a Personal Genome Machine (PGM TM , Life Technologies). Further details are given in Supporting Information Methods and Supporting Information Table IV. Whole VDJ sequences are available upon request.
VDJ cloning and Sanger sequencing for PBMC of UPNs #1313 and #1525. VDJ rearrangements of the IgH locus were first identified in diagnostic biopsies for UPNs #1313 and #1525 according to BIOMED-2 guidelines with some modifications [20] . Clonal VDJ rearrangement were then searched in paired PBMC with a highly sensitive PCR using a consensus FR1 forward primer and a CDR3-specific reverse primer. Detailed procedures are reported in Supporting Information Methods. After cloning of the PCR products, VDJ sequences were obtained with Sanger method and analyzed using the IMGT/V-Quest tool (http://www.imgt.org) [21] .
Phylogenetic trees. Whole Ig-HTS sequences were submitted to IMGT High/VQuest platform (http://www.imgt.org) version 1.4 with the reference directory release 201511-4 [22] . Briefly, clone-related productive sequences ranging from FR2 region to the end of the CDR3, sharing the same IGHV gene and the same CDR3 length as well as presenting 60% of homology for the CDR3 amino-acids sequence, were retained for phylogeny. Due to a very low sequencing efficiency for UPN#955, only shorter VDJ sequences (i.e., FR3 to CDR3) were included in the phylogenetic analysis. All dominant clonotype selected by our pipeline were also confirmed by direct Sanger sequencing. Phylogenetic trees were obtained using SeaView software platform using neighbor joining algorithm, version 4.5.4 [23] and jsPhyloSVG (http:// www.jsphylosvg.com) [24] . A maximum parsimony algorithm was also used as a control on the same datasets. Details are given in Supporting Information Methods.
Functional analysis: N-glycosylation sites and pressure of antigen driven selection. Potential N-glycosylation sites (i.e., NXS/T, where X is different from P) were searched for using the NetNGlyc1.0 online tool (http://www.cbs.dtu.dk/services/NetNGlyc/). Pressure of antigen driven selection was evaluated using BASELINe version 1.3 (Bayesian Estimation for Antigen Driven Selection in Immunoglobulin sequences, available at http://www.selection.med.yale.edu/baseline/ ) [25] , with the human S5F algorithm [26] , and the focused binomial test [27] .
Non-Ig gene PGM sequencing, single nucleotide variant (SNV), and copy number variant (CNV) analysis. Thirty four genes relevant to lymphomagenesis (listed in Supporting Information Table V) were analyzed using the multiplexed PCR-based targeted library Ion AmpliSeq TM technology, as previously described [28] . Sequencing performances and whole nucleotide variations are respectively given in Supporting Information Table VI and Supporting Information Data as a combined .vcf file. The complete list of variant selected as pathogenic [28] is given in Supporting Information Table VII. Details on sequencing parameters and bioinformatics pipeline are given in Supporting Information Methods. Briefly, only variants predicted to be nonpathogenic by both SIFT and CADD prediction algorithms were not considered for analysis. Sanger validation was also performed when necessary. CNV analysis was performed using the ONCOCNV package [29] .
Statistics. Fisher's exact test and Mann-Whitney U test were used considering P value <0.05 as significant.
Results

Characteristics of the selected patients
In order to get new insights on the biological relevance of early and late divergence, we retrospectively included nine DLBCL cases who classically relapsed with high grade lymphoma, but also three cases that have relapsed with a low grade lymphoma related to the initial clone, and two non relapsing cases only monitored with PBMC. All patients were diagnosed between 1994 and 2004, followed at our institution and initially retained for the study based on the availability of matched samples. Main characteristics of the series are presented in Supporting Information Table I . Based on recent publications [30, 31] , our parsimonious GEP analysis was chosen as the reference method for COO classification with the exception of UPN#1178 and UPN#1306. For these two latter cases, classified as "undetermined" with GEP analysis, IHC-based classification was considered (Supporting Information Table III) . Overall, our cohort included 10 ABC and 4 GCB DLBCLs. Twelve had at least two paired biopsies (i.e., diagnosis and relapse) and 2/14 were still in remission at the time of analysis. The two nonrelapsing patients were thus only monitored with PBMC collected during follow-up. For 9/12 relapsing cases, the relapse biopsy showed the same histological features (i.e., high grade lymphoma) whereas three patients relapsed with a low grade lymphoma, respectively two FLs and one marginal zone lymphoma (MZL). PBMC isolated at diagnosis were available for 4/12 relapsing cases. We could thus study the evolution of intraclonal diversity between GCB and ABC subtypes, extend the exploration to PBMC and investigate DLBCL cases with low grade lymphomas at relapse.
Relapse can arise either from an early divergent or a late divergent scenario diagnostic biopsy was determined and served as a molecular tracer for the subsequent samples (biopsies and/or PBMC). All clonally related sequences were realigned with the germline reference in order to obtain phylogenetic trees for the 12 relapsed patients. We could thus observe two relapsing patterns in our series: 5/12 (42%, 4 ABC and 1 GCB) showed an early divergence from the initial clone at diagnosis while 7/ 12 (58%, 5 ABC and 2 GCB) showed a late divergence ( Fig. 1 and Supporting Information Fig. 1 ). Results from neighbor joining and maximum parsimony algorithms were concordant (Supporting Information Fig. 2 ). As previously described [14] , we observed no difference in the prevalence of the two relapsing modes according to COO subtype, a trend that should be confirmed in larger series. Considering the statistical limitations due the size of our series, the type of divergence did not significantly influence the elapsed time between diagnosis and relapse either (respectively 55.0 6 42.7 and 23.9 6 19.8 months for early and late divergence, Mann-Whitney U test: P value 5 0.20) (Fig. 2A ).
DLBCL relapse is not driven by antigen selection pressure
We next evaluated the molecular diversity in the VDJ locus at diagnosis and relapse for both relapsing modes. We first calculated the VDJ mutation frequency in comparison to the germline sequence (i.e., number of mutated sites/VDJ length in base pairs). VDJ mutation frequency was similar between diagnostic and relapse samples and between late and early divergent modes for all but two cases (Fig.  2B ). Indeed, the two patients who relapsed with low grade histology compatible with a FL (UPN#688 and UPN#1178), both belonging to the early divergent group, showed a higher rate of mutations at relapse than at diagnosis. This result indicates a high molecular diversity in these two samples. The remaining case with a low grade lymphoma at relapse (UPN#1608, ABC to MZL) belonged to the late divergent group and did not show a higher molecular diversity in the VDJ locus than the other samples.
As VDJ mutations are prone to an Ag-driven process of selection in GC, we also searched for changes in functional features, such as gain or loss of potential N-glycosylation sites (NXS/T motifs) or features of Ag selection pressure. In our series, 7/14 cases presented potential N-glycosylation sites that were conserved from diagnosis to relapse or during follow-up on PBMC. Of these, 5/7 (71%) used the IGHV4-34 gene and conserved the NXS/T site of their germline counterpart. One of these cases using the IGHV4-34 gene (UPN#1525) also presented two additional sites. The 2/7 other cases (UPN#478 and UPN#1540) gained one N-glycosylation site compared to their germline counterpart (respectively IGHV3-30*14 and IGHV1-2*02). Thus, we could not conclude as to whether there exists an N-glycosylation site selection pressure during DLBCL evolution in our series.
We next evaluated the Ag-driven selection of SHM in the VDJ sequences. As expected for DLBCL samples [32] , IGHV locus was highly mutated in both early and late divergent cases (mean of IGHV gene homology: 90.2 and 84.7%, respectively, Mann-Whitney U test: P value 5 0.329). At diagnosis, both early and late divergent groups presented features of negative selection in the FR regions (i.e., excess of silent mutations than expected). Indeed, mean selection strengths calculated with the BASELINe tool were 20.930 and 20.862 for early and late divergent groups respectively (associated P values 5 5.27 3 10 25 and 8.11 3 10 27 ) and this profile in FR regions was conserved at relapse (Fig. 2C) . Conversely, profiles for Ag selection pressure in CDR regions were more heterogeneous (Fig. 2C) . Among the 12 relapsed cases, 9/12 (75%) showed no significant features for either positive or negative selection (i.e., selection strength not significantly different from zero with a P value threshold equal to 0.05). The three remaining cases (3/12, i.e., 25%) harbored significant features for negative Ag selection pressure in their CDR regions. Among them, one (UPN#955) belonged to the early divergent group whereas the two others (UPNs #1415 and #1001) were late divergent cases. Finally, comparison between paired diagnosis and relapse clones did not highlight any significant evolution of the Ag selection pressure on tumor B-cells.
Targeted high-throughput sequencing of non Ig-gene and cytogenetics confirmed the two modes of divergence
We used both targeted HTS of a panel of 34 genes and cytogenetics to consolidate Ig-HTS data and divergence scenarios. Detailed results for targeted HTS (obtained for 8/12 relapsed pairs) are shown in Supporting Information Fig. 3A . No recurrence was observed between patients in the whole series. For all but one patient (UPN#688), when a gene was mutated both at diagnosis and relapse we found the same single nucleotide variant (SNV) in the two samples. For UPN#688, the single TNFAIP3 mutation detected at diagnosis (marked with a red circle in Supporting Information Fig. 3A) was different from each of the two mutations present at relapse. Overall, both epigenetic deregulation and NF-jB signaling were the most frequently impacted (Supporting Information Fig. 3B ) and their alterations were highly conserved between diagnosis and relapse (5/8 pairs, Fig. 3B ). This trend should also be confirmed in larger DLBCL studies.
Targeted HTS and cytogenetics confirmed the two relapse modes as primarily highlighted by Ig-HTS and VDJ phylogenetic trees ( Fig.  1 and Supporting Information Fig. 1 ). The evolution of variant allele frequencies in paired samples clearly showed that loss of SNVs occurred in 3/4 (75%) early divergent cases analyzed by targeted HTS and none of the late divergent cases (Fig. 3A,B) . This observation was improved by including CNV analysis; means of shared genetic abnormalities detected by targeted HTS were 27.0 and 81.5%, respectively, for early divergent and late divergent pairs (Mann2Whitney U test: P value 5 0.0031) (Fig. 3C ). This result was in agreement with the evolution from a less mutated precursor in early divergent cases and confirmed VDJ phylogenetic trees. Similar profiles of divergence were observed using cytogenetics although paired cytogenetic data were only available for four early divergent and two late divergent pairs ( Fig. 1 and Supporting Information Fig. 1 ). All together, integrated analysis of the three molecular markers (i.e., VDJ-based phylogeny, targeted HTS and cytogenetics) excluded the hypothesis of linear evolution from a mutated clone (targeted HTS) with genomic loss of the mutated allele in the cases of early divergence but also revealed an unexpected evolution in VDJ late divergent cases. Indeed, if 5/5 of early divergent cases showed "oncogenetic" divergence, targeted sequencing and/or cytogenetics could highlight divergent "oncogenetic" evolution rather than linear evolution in at least 2/7 VDJ late divergent cases (UPNs #1415 and #1001, Supporting Information Fig. 1) .
Finally, we specifically analyzed the three cases that had relapsed with a low grade lymphoma. The total number of genetic abnormalities detected by targeted HTS seemed to be lower for this three cases and this trend was observed for both diagnostic (high grade) and relapse (low grade) paired samples (Fig. 3D ).
Circulating tumor cell (CTC) detection based on VDJ specific rearrangement revealed a higher level of clonal architecture complexity than expected at the time of diagnosis
To gain insights into the intraclonal diversity of DLBCL at diagnosis, we performed Ig-HTS on PBMC samples. Clonally related VDJ sequences were found for four relapsing cases, revealing the initial presence of CTC (Fig. 4) . Conversely, and despite an acceptable sequencing depth (Supporting Information Table III) , Ig-HTS failed to detect CTC in the two nonrelapsing cases, both in diagnostic PBMC and in PBMC isolated during follow-up several months later. For these two remaining cases, we designed CDR3-specific reverse primers and attempted to amplify specific clonal rearrangement by PCR using BIOMED-2 consensus FR1 forward primer. For UPN#1525, CTC were still undetectable at 43.4 months after treatment whereas clonally related sequences were found in PBMC of UPN#1313. For this latter case, PBMC were positive both at diagnosis and during follow-up, despite the persistence of a clinical complete remission. The amplified VDJ rearrangements were cloned before direct Sanger sequencing. The result did not allow for the quantification of CTC subclones but a phylogenetic tree was able to be built (Fig. 4) . Overall, in 4/5 cases with detectable CTC at diagnosis (i.e., UPN#1291, UPN#1415, UPN#1541 relapsing cases and UPN#1313 nonrelapsing case), at least one circulating subclone showed a distinct pattern of SHM and could correspond to early divergence (Fig. 4) . Furthermore, for UPN#1291 and UPN#1541, at least one of these CTC clones at diagnosis was highly similar to the major one observed at relapse (i.e., similarity of SHM patterns in their VDJ sequences).
Elevated intratumoral diversity of DLBLC at diagnosis as highlighted by one case
Finally, the clinical history of UPN#1291 seems to represent the perfect illustration of the high level of diversity in DLBCL tumor burden, already present at the time of diagnosis. This patient harbored clinically suspected malignant lymphoma with an important urethral mass. This mass was subjected to a first biopsy that confirmed the DLBCL diagnosis. On this sample, Ig-HTS detected a first group of VDJ clones (Supporting Information Fig. 4A ), but cell culture for cytogenetics failed. Nevertheless, targeted HTS detected, notably, a frameshift indel in KMT2D and a heterozygous deletion of TNFAIP3 associated with a disrupting mutation of the other allele. As this first biopsy was too poor to enable an exhaustive histological analysis, a second biopsy was indicated (inguinal lymph node referred to as the second biopsy at diagnosis). Here, VDJ sequencing detected another pattern of SHM in the clonal rearrangement, corresponding to an early divergence from the first clone (Supporting Information Fig.  4A ). Indeed, targeted HTS detected a different pattern of mutations (Supporting Information Fig. 3A) . Among other alterations, this second clone presented a homozygous deletion of TNFAIP3 with a heterozygous deletion of TP53, confirmed by cytogenetics (del(17)(p11), Supporting Information Table I ) ,but without mutation of the second allele. Strikingly, CTC could be detected at diagnosis by Ig-HTS and revealed circulating clones different from those of the first biopsy (early divergence), but similar to those of the second biopsy (late divergence) (Supporting Information Fig. 4A ). Despite conventional immunochemotherapy, this patient relapsed less than one year later. A new biopsy revealed a VDJ clone similar to the ones detected in CTC and in the second biopsy at diagnosis. Targeted HTS confirmed the phylogeny observed with VDJ sequencing (Supporting Figure 4 . Evidence for circulating tumor cell in peripheral blood mononuclear cell using Ig-HTS. PBMC were collected at diagnosis and during follow-up for five patients. Clone related VDJ sequences were searched using Ig HTS and were included in phylogenetic trees. The color code for sample origin (i.e., biopsies at diagnosis, biopsies at relapse, PBMC at diagnosis and PBMC collected during follow-up) is indicated in the figure. Black bars represent the relative abundance (%) of each clone and the external gray circle indicates the upper limit of 100% as in previous data. Divergent clones found in diagnostic PBMC and corresponding to circulating tumor cells (CTC) are indicated with a red line and a star, as indicated in the figure. CTC: circulating tumor cells; Ig-HTS: immunoglobulin high throughput sequencing; PBMC: peripheral blood mononuclear cell; VDJ: for variable-diversity-junction corresponding to the variable region of the immunoglobulin heavy chain. Information Figs. 3A and 4B) . The pattern of genetic alterations within the relapse clone was very similar to that of the second biopsy at diagnosis, with 6/13 common SNVs or CNVs. For this patient, the first oncogenic event of the ones detected, is probably a monoallelic deletion of the TNFAIP3 gene. At the time of relapse, a monoallelic deletion of TP53 was also associated with an acquired pathogenic mutation of the second allele (p.R158H, 80/91 mutated reads). This mutation could not be detected in either of the two successive diagnostic biopsies (respective sequencing depths: 124X and 85X).
Discussion
The purpose of this study was to evaluate the relations of intraclonal diversity on the clinical evolution of DLBCL using paired diagnostic and relapse samples. Our analysis relied on a combined approach to evaluate intra-tumoral diversity, using Ig-HTS, cytogenetics and targeted sequencing of a panel of 34 genes relevant for lymphomagenesis. Using Ig-HTS, we first confirmed the previous findings [14] that DLBCL relapse can emerge according to two scenarios: an early divergent scenario, where the relapsing clone independently evolves from a common progenitor, and a late divergent scenario, where the relapsing clone usually derives from the diagnostic clone. Combining targeted HTS and cytogenetics to Ig-HTS we showed oncogenetic divergent evolution in the IGHV early divergent group but, interestingly, we also found such evolution in 2/7 IGHV late divergent cases. Furthermore, our series of 12 relapsing patients was enriched with PBMC isolated at diagnosis for four of them and also included two additional nonrelapsing patients with only PBMC isolated both at diagnosis and during follow-up, several months after treatment. These PBMC enabled the detection of CTC, and, altogether, our data highlight the complex clonal architecture of DLBCLs.
The two modes of divergence at relapse had previously been demonstrated in B-cell Non Hodgkin Lymphomas (B-NHLs) harboring a BCL2-IgH translocation by Ruminy et al. [12] and other authors in FLs, using either analysis of Sm mutations patterns, V(D)J Sanger sequencing [13] , Ig-HTS [33] , BCL2 mutations [34] or whole exome sequencing [35] . Similarly to what had been shown by Jiang et al. [14] , our results demonstrated that evolution of Ig SHM, SNVs and CNVs, explored by HTS, as well as cytogenetic abnormalities, was parallel in early divergent relapsed DLBCLs. Interestingly, we found here that discrepancies could occur in IGHV late divergent group, highlighting that relapses appeared to be the consequence of selective pressure following lymphoma treatment. Jiang et al. [14] also exploited early divergent pairs and ultradeep sequencing to demonstrate that epigenetic alterations might represent one of the earliest genetic events promoting DLBCLs. The sequencing depth used in this study did not allow enough sensitivity to clearly highlight the precocity of such genetic alterations. Our sequencing strategy was rather used as a control of the subclonal evolution revealed by Ig HTS. Nevertheless, lymphoma initiation through early epigenetic alterations was clearly confirmed in FLs in reports that have focalized on deep sequencing on serial samples [35] [36] [37] , as well as in mouse models [38, 39] . Furthermore, Green et al. [37] also demonstrated that impairment of immune surveillance may cooperate in early phases of tumor B-cell development. Conversely, mutations affecting NFjB signaling (through MYD88 or TNFAIP3 mutations) [36] or alteration of cell cycle as well as apoptosis [35] were frequently acquired in transformed FLs. These kinds of alterations are more frequently observed in DLBCLs, even in early stages. Thus, despite that DLBCLs may occur through a distinct and a more aggressive natural history, the study of Jiang et al. and our results show that clonal evolution may not be as linear as it could be anticipated for this entity.
Mechanistically, AID is responsible for Ig SHM but also for non-Ig gene mutations (aberrant SHM) in at least 50% of DLBCLs, as well as Ig and non-Ig chromosomal translocations in these malignancies [40] [41] [42] [43] . Thus, the parallelism between molecular markers might rely, at least partially, on AID activity. Zuckerman et al. [45] also proposed that AID-mediated evolution was directly dependent on the duration in time of the tumor clone evolution [44] . In line with this argument, Ruminy et al. had demonstrated that relapse of early divergent BNHLs with BCL2-IgH translocation frequently occurred later, leading to the hypothesis that subsequent tumor transformation from a premalignant precursor was effectively time-dependant in such cases. Thus, the existence of a committed BCL2-IgH1 precursor several years before FL diagnosis had already been demonstrated [45] . In our series as well as in that of Jiang et al., no significant difference in the time elapsed from diagnosis to relapse could be observed between early and late divergent cases. Although this should be confirmed in larger cohorts, both observations in DLBCL could result from the rapid evolution of these aggressive entities.
High levels of SHM and features of antigen-selection pressure have often been detected in previous studies on DLBCLs [32, 46] . In our series, consistent with previous results of Jiang et al. [14] , both GCB and ABC DLBCLs presented variable levels of intraclonal diversity in the IGHV locus. Even if GCB-DLBCL should be more prone (but not exclusively) to ongoing somatic mutations, as reflected by cloning approaches [47] , sequencing depth reached by HTS allowed the observation of VDJ-related subclones also in ABC-DLBCL. We observed similar mutation frequencies in the V(D)J sequences between early and late divergent cases and between diagnostic and relapse samples, with the exception of UPN#688 and UPN#1178 which both relapsed with low grade FL. For these cases, this might be linked to the ongoing mutation process of the Ig locus in FLs [33, 48, 49] . As expected, we found a negative selection in FR regions of both early and late divergent groups that might reflect the necessity of preserving the global structure of the Ig [44] . CDR regions profiles globally showed the absence of significant Ag selection pressure and even features of negative selections in few cases, consistent with previously reported results [44] . Altogether, FR and CDR mutation patterns might reflect either (i) the conservation of an optimal CDR reactivity against Ag or (ii) super-Ag stimulation of tumor B-cells [32, 44] . Integrated to previous results showing divergent oncogenic evolution in some IGHV late divergent cases, these results showed that if BCR triggers tumor B-cell development and is mandatory to its maintenance [50] , oncogenetic events may be the main driving force for DLBCL relapse, mainly selected by treatment.
Our series also included three patients initially diagnosed with DLBCL who relapsed with VDJ-related low grade B-NHLs (i.e., two FLs and one MZL, for respectively UPN#688, UPN#1178 and UPN#1608). The two patients who had relapsed with FLs belonged to the early divergent group whereas the latter harbored features of late divergence. Relapses from high grade to low grade lymphomas had already been described [51] and naturally raised the question of whether initial DLBCL corresponded to a transformed B-NHL or whether the "relapse" was a genuine "second disease" that occurred from a premalignant precursor. Notably, de novo GCB-DLBCLs and transformed FLs (tFLs) share most of their histological features [35, 47] . In this context, Pasqualucci et al. [35] described a genetic signature specific to tFL. Here, tFL diagnosis could thus be discussed for UPN#1178, as specific genetic alterations were detected (BCL2 translocation, CREBBP and STAT6 mutations), whereas none were present in paired samples of UPN#688.
By exploiting PBMC isolated at time of diagnosis, we showed that intraclonal diversity also exists beyond the scope of the biopsy. Interestingly, in the six cases with parallel samples at diagnosis, we could detect CTCs in 5/6 patients with at least one divergent VDJ subclone for four of them. In two cases, a CTC clone similar to the ones detected at relapse was already present in blood (with VDJ analysis only). Thus, our data clearly demonstrates that addressing the question of intraclonal diversity in DLBCLs might be more relevant at the whole body scale than at the single biopsy scale. As it has been reported for FLs, tumor B-cell clones of DLBCL might also appear in one initial lymph node (or other B-cell rich area) where a first level of diversification has been described [52] and then spread through lymphatic or peripheral blood flow [49, 53] . After homing in secondary favorable niches (lymph nodes, bone marrow . . .), parallel evolution of tumor B-cells can occur [49, 53] leading to a highly complex dynamics of tumor B-cells [54] . Indeed, divergent but clonally related CTCs have been reported in primary central nervous lymphomas (PCNLs) [55] , a specific entity of DLBCLs. In our series, UPN#1291 was a perfect example of intra-tumor diversity at diagnosis, with two distinct dominant subclones in two distinct biopsies (with one harboring a TP53 alteration), and with CTC clones at diagnosis that were similar to the ones at relapse (at least with Ig-HTS).
Finally, to address the question of DLBCL molecular profiling toward the goal of personalized therapy, this study highlighted that intraclonal diversity at the whole body scale might be of particular interest. Peripheral blood, by potentially melding together different tumor-related subclones, should be used in parallel to a tumor biopsy, at least for patients with initial multiple localizations and/or advanced stages. Recent publication have demonstrated the feasibility and the superiority of circulating cell-free DNA in monitoring minimal residual disease (MRD) of DLBCL using Ig-HTS when compared to PBMC [56, 57] . Furthermore, we have shown in our institution that MRD could also be assessed using targeted HTS of non-Ig genes on such circulating cell-free DNA [58] . In this latter study, we specifically searched for mutations previously detected in the biopsy but we did not exploit the potential divergence of circulating DNA from the unique diagnostic biopsy. Here, by using Ig-HTS on PBMC, we highlight that a higher degree of intraclonal architecture may be relevant for molecular profiling of DLBCL cases. In conclusion, this work, together with reported results discussed above, represents a rationale to consider sequencing of circulating cell-free DNA in future clinical studies.
